Metalloproteinase inhibitors would also prevent CD16 shedding form the surface of NK cells, a mechanism that naturally occurs following CD16 ligation (133, 134) yet is dysregulated in HIV infection and cancer, thereby decreasing ADCC activity and cytotoxicity against HIV-infected or tumor cells. The gene discussed is FCGR3A; the disease is cancer.